What OSRX does

OSRX is an FDA-registered 503B outsourcing facility that compounds sterile ophthalmic medications for U.S. prescribers and their patients, operating exclusively on a cash-pay basis without insurance billing. Founded in 2019 in Missoula, Montana (originally as Pinnacle Compounding), the company is now licensed in all 50 states and serves more than 10,000 prescribers nationwide, including ophthalmologists, optometrists, surgical centers, and ambulatory surgery centers.

Its core product portfolio, marketed under the OMNI brand, combines multiple active pharmaceutical ingredients into single-dose sterile bottles — covering post-operative care (prednisolone/moxifloxacin/bromfenac/ketorolac combinations), glaucoma combination therapy (timolol/bimatoprost/brimonidine/dorzolamide), low-dose atropine (0.01%–0.05%) with reduced BAK preservative for pediatric myopia management, ophthalmic dilation, and intracameral injections. Supporting infrastructure includes an EMR/e-prescribing-integrated Prescriber Portal, a separate bulk ordering portal for surgical centers, a patient portal with AutoRefill enrollment, and dual NABP accreditations (Drug Distributor and Healthcare Merchant) earned in 2025 following an 18-month review.

OSRX generates revenue through per-prescription transactions (direct-to-patient shipments via USPS/FedEx and bulk orders to surgical centers) and through its monthly AutoRefill subscription program priced from $20 per bottle — offering up to 60% savings versus retail pharmacy pricing. The company is privately held with no disclosed institutional investors, led by President & CEO Anthony Sampietro (former Alcon, Abbott, J&J, Optimedica, LENSAR) and Chief Pharmacy Officer Amy Frost, PharmD.

Name

OSRX

Legal name

OSRX, Inc.

Website

https://osrxpharmaceuticals.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

OSRX is an FDA-registered 503B outsourcing facility that compounds and ships sterile ophthalmic medications cash-pay to U.S. prescribers and patients across all 50 states, serving ophthalmologists, optometrists, and surgical centers with combination post-op, glaucoma, and low-dose atropine formulations.

Ownership category

akta.pro rank

Headquarters

HQ city

Missoula

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Direct-to-Patient Prescription Fulfillment: OSRX ships patient-specific compounded medications directly to consumer homes after prescription is submitted by prescriber. Patient pays out-of-pocket (cash-pay model); no insurance billing. Revenue realized per transaction at point of prescription fulfillment and shipment.
2. AutoRefill Subscription Program: Monthly automatic billing and shipment of maintenance medications (primarily glaucoma combination therapies) to enrolled patients. Creates predictable recurring revenue stream through subscription-like mechanics. Medications start at $20/bottle with AutoRefill pricing.
3. Bulk Order Fulfillment for Surgical Centers: Surgical centers and practices order compounded medications in bulk quantities for in-office dispensing. Revenue realized per bulk order transaction with volume-based pricing.
4. Volume Discount Programs: Practices ordering higher volumes receive discounted pricing, creating tiered transaction revenue based on order frequency and quantity.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels10 records

Core offering

OSRX operates an FDA-registered 503B outsourcing facility that compounds sterile ophthalmic medications by combining multiple active pharmaceutical ingredients (APIs) into single-dose ophthalmic solutions. Products serve post-operative care, glaucoma management, myopia control, and ophthalmic injection use cases, distributed via direct-to-patient cash-pay shipments and bulk orders to surgical centers and ophthalmology practices.

Product overview

OSRX is an FDA-registered 503B outsourcing facility offering a unified portfolio of compounded ophthalmic medications under the OMNI brand. The core product line includes Post-Op Care medications (combination Prednisolone/Moxifloxacin/Bromfenac/Ketorolac formulations), Glaucoma Care/Combination Therapy (Timolol/Bimatoprost/Brimonidine/Dorzolamide combinations), Low-Dose Atropine+ (0.01%-0.05% for myopia management), Ophthalmic Dilation (Tropicamide/Phenylephrine), and Ophthalmic Injections (Dexamethasone/Moxifloxacin). Supporting platforms include the Prescriber Portal for prescription management and Bulk Ordering Portal for facility orders. The AutoRefill Program add-on provides automatic monthly refills at up to 60% savings. All medications are cash-pay only, combining multiple active ingredients into single-dose bottles to simplify patient regimens.

Differentiator

Problem solved

Functional benefit

Products and services

• Post-Op Care Combination Medications Compounded sterile ophthalmic solutions combining multiple active ingredients (Prednisolone Phosphate, Moxifloxacin, Bromfenac, Ketorolac) into single bottles for post-surgical care following cataract, LASIK, and other ophthalmic procedures. Available in 5mL and 8mL bottles.
• Glaucoma Combination Therapy Compounded glaucoma medications combining multiple agents (Timolol, Bimatoprost, Brimonidine, Dorzolamide) into single bottles for glaucoma management. Available in 2mL and 5mL sizes. Includes formulations such as Timolol + Bimatoprost, Timolol + Brimonidine + Dorzolamide, and Bimatoprost + Brimonidine + Dorzolamide + Timolol.
• Atropine+ Low-Dose Atropine Low-dose atropine formulations (0.01%, 0.025%, 0.05%) combined with lubricant and 50% less BAK preservative (0.005%) for pediatric myopia management. Shelf-stable formulations available in 3.5mL bottles.
• Ophthalmic Dilation Drops Compounded Tropicamide 1% and Phenylephrine HCl 2.5% combination for ophthalmic dilation. Available in 2mL and 10mL sterile solutions for diagnostic and pre-operative pupil dilation.
• Ophthalmic Injections Compounded sterile intracameral injections including Dexamethasone Phosphate 0.1% + Moxifloxacin HCI 0.5% and Moxifloxacin HCI 0.1% for intraoperative use. Available in 1mL vials for surgical centers.

Quantifiable outcome

• Up to 60% cost savings vs retail pharmacy pricing for patients
• +8 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature5 records

Partnerships

Six partnerships are on record, tiered core and supporting.

• Sam PetersencoreGTM or Marketing Partner · 20 April 2026Professional rodeo athlete and Montana native, 2025 World No. 2 bareback rider and Wrangler National Finals Rodeo average champion. Partnership includes national marketing campaigns, event appearances, and digital content series throughout 2026. Represents OSRX brand values of precision, preparation, and accountability. Both share Montana roots and competitive mindset built on performance.
• Truly AdamscoreGTM or Marketing Partner · 1 February 202615-year-old American racing driver and two-time World Karting Champion pursuing Formula 1 pathway. First American to finish on podium at FEED Racing Volant F4 Finals in France. Partnership supports rising motorsports prodigy representing grit and determination against larger well-funded opponents—mirroring OSRX's position as upstart compounder challenging Big Pharma.
• Ocular Science® (affiliate)coreOthersMedical Advisory Board members for Ocular Science (an OSRX affiliate) include Drs. Wörtz, Tauber, Gupta, Fram, Beckman, Sarkisian, Griffiths, Waring, and others. These ophthalmic opinion leaders provide clinical guidance and have financial interests in the company. Multiple physicians serve as reference customers and content contributors.
• EMR/E-Prescribing System VendorssupportingTechnology or IntegrationTechnical integration enabling prescribers to submit prescriptions directly from their existing electronic medical records and e-prescribing systems to OSRX. Allows seamless prescribing workflow without additional portals.
• USPSsupportingOthersPrimary shipping carrier for direct-to-patient prescription deliveries. Standard shipping 3-7 business days. OSRX texts tracking information to patients upon shipment.
• FedExsupportingOthersExpedited shipping option for facility bulk orders (2-day delivery) and patient orders requiring faster delivery than standard USPS. Additional fees apply for expedited service.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• ImprimisRx: ImprimisRx was OSRX's most direct ophthalmic compounder competitor, offering similar cash-pay combination drops (prednisolone-based, doxycycline, atropine) targeted at ophthalmologists and optometrists. Its recent market exit creates the share-gain opportunity for OSRX, and its product categories, cash-pay model, and prescriber targeting model were nearly identical.
• Avella Specialty Pharmacy: Avella is a national specialty and compounding pharmacy operating 503A/503B-style sterile compounding capabilities with ophthalmic and specialty therapeutic focus. It competes for ophthalmology prescription volume via cash-pay and direct-to-patient fulfillment models broadly comparable to OSRX's go-to-market.
• Pentec Health: Pentec Health is a specialty sterile compounding pharmacy providing patient-specific compounded medications, including ophthalmics and injectables, with direct-to-patient distribution. Its compounding-plus-specialty-distribution model and sterile preparation capabilities are closely comparable to OSRX's 503B outsourcing facility operations.
• Wedgewood Pharmacy: Wedgewood Pharmacy is one of the largest U.S. compounding pharmacies, offering sterile and non-sterile compounded preparations including ophthalmic formulations, with nationwide distribution to prescribers and patients. Its scale, regulatory positioning, and prescriber-direct model are comparable to OSRX's ophthalmic compounding focus.

Broad incumbents

• Bausch + Lomb (Bausch Health): Bausch + Lomb is one of the world's largest ophthalmic pharmaceutical and device companies, offering FDA-approved branded combination drops and post-operative ophthalmic medications. OSRX competes for the same prescriber mindshare and prescription volume, but B+L sells branded, FDA-approved alternatives at retail pharmacies rather than cash-pay compounded products.
• Alcon: Alcon is a global leader in ophthalmic pharmaceuticals and surgical devices, including post-cataract and glaucoma drugs. OSRX CEO Anthony Sampietro's prior tenure at Alcon makes the competitive overlap direct; Alcon's FDA-approved branded portfolio competes with OSRX's compounded combination therapies across the same prescribers.
• Allergan (AbbVie): Allergan, an AbbVie company, is the dominant player in ophthalmic pharmaceuticals including branded glaucoma drops (e.g., combinations involving bimatoprost) that overlap directly with OSRX's compounded glaucoma combination portfolio. It competes at the same prescribers but with FDA-approved, insurance-reimbursed products.

Emerging players

• Ocular Therapeutix: Ocular Therapeutix is a specialty biopharmaceutical company developing ophthalmic drug delivery and sustained-release products for post-surgical and chronic ophthalmic conditions. Its focus on ophthalmic drug delivery makes it comparable to OSRX in target market, though it pursues FDA-approved drug-device combinations rather than compounding.
• Sun Pharmaceutical Industries: Sun Pharma, through its Taro/Sun Ophthalmics franchise, manufactures and distributes generic and branded ophthalmic pharmaceuticals in the U.S. including glaucoma and post-operative drugs. It competes with OSRX in ophthalmic pharmaceutical distribution at scale, though via FDA-approved generic/branded products rather than compounded formulations.

Others

• Carl Zeiss Meditec: Carl Zeiss Meditec is a global ophthalmic medical technology company operating in surgical ophthalmology (cataract, refractive). While not a compounder, it sells into the same ophthalmic surgical practices that prescribe OSRX's post-operative combination drops, and competes indirectly for share of ophthalmic surgical workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/OSRXinc
• LinkedInlinkedin.com/company/osrxinc
• Instagraminstagram.com/osrxinc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OSRX